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Abstract A major goal of immunotherapy for cancer is
the activation of T cell responses against tumor-associated
antigens (TAAs). One important strategy for improving
antitumor immunity is vaccination with peptide variants of
TAAs. Understanding the mechanisms underlying the
expansion of T cells that respond to the native tumor
antigen is an important step in developing effective pep-
tide-variant vaccines. Using an immunogenic mouse colon
cancer model, we compare the binding properties and the
TCR genes expressed by T cells elicited by peptide variants
that elicit variable antitumor immunity directly ex vivo.
The steady-state affinity of the natural tumor antigen for
the T cells responding to effective peptide vaccines was
higher relative to ineffective peptides, consistent with their
improved function. Ex vivo analysis showed that T cells
responding to the effective peptides expressed a CDR3b
motif, which was also shared by T cells responding to the
natural antigen and not those responding to the less
effective peptide vaccines. Importantly, these data
demonstrate that peptide vaccines can expand T cells that
naturally respond to tumor antigens, resulting in more
effective antitumor immunity. Future immunotherapies
may require similar stringent analysis of the responding T
cells to select optimal peptides as vaccine candidates.
Keywords Peptide vaccines  T cell repertoire 
Tumor antigens  Peptide variants
Introduction
Increased frequencies of cytotoxic T lymphocytes (CTLs),
which recognize antigenic peptides from tumors presented
by major histocompatibility (MHC) class I molecules, cor-
relate with improved cancer patient survival [1]. CTLs and
the effector molecules they produce are critical in the elim-
ination of cancer cells [2, 3]; however, they are also subject to
regulatory mechanisms. Tumor-specific CTLs often recog-
nize peptides derived from tumor-associated antigens
(TAAs). One important strategy for improving antitumor
immunity and overcoming these self-tolerance mechanisms
is vaccination with peptide variants of TAAs (also known as
mimotopes, heteroclitic peptides, peptide analogues, or
altered peptide ligands) that improve binding to either MHC
molecules [4] or tumor-specific T cell receptor (TCR) mol-
ecules [5, 6]. These vaccines stimulate the expansion of the
often low-affinity TAA-specific T cells that escape negative
selection during development [7, 8] and are suboptimally
activated by native tumor antigens [9, 10]. Clinical trials
have shown increased frequencies of TAA-specific T cells
following vaccination with peptide variants, demonstrating
the potential of antigen-specific immunotherapy [11].
Peptide variants are most often selected as vaccine
candidates because they bind with stronger affinity or
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stimulate TAA-specific T cells more effectively than the
native tumor antigen in vitro. Paradoxically, vaccination
with these variants often elicits T cells with diminished
antitumor activity relative to T cells that naturally respond
to native tumor antigens [12–15]. Using the CT26 trans-
plantable tumor model [7, 16], we previously showed that
vaccination with variants of the immunodominant peptide,
gp70423–431 (AH1), elicited variable antitumor immunity
[17, 18]. These peptides robustly stimulated the tumor-
specific T cell clone used to identify the variants and
elicited more tumor-specific T cells from the endogenous
repertoire of BALB/c mice than the native AH1 peptide
[17, 18]. However, vaccination with these peptides elicited
a range of antitumor immunity. The ineffective peptides
elicited T cells that failed to kill AH1-loaded target cells or
produce IFNc after stimulation with the native tumor
antigen [17]. Surprisingly, these functionally deficient T
cells produced IFNc after stimulation with the variant
peptide used in the vaccine, suggesting that the ineffective
peptide variants were not antagonists or partial agonists, as
in other systems [19].
Understanding the mechanisms underlying the expansion
of T cells that respond poorly to native tumor antigens is an
important step in developing effective peptide-variant vac-
cines. The repertoire of T cells responding to peptide variants
is often different than the repertoire of T cells responding to
native tumor antigens [10, 12, 20, 21]. As addressed in this
study, we hypothesized that the effective peptide variants
likely elicited a different repertoire of tumor-specific T cells
that expressed TCRs with higher affinity for the native tumor
antigen. Since in vitro expansion of tumor antigen-specific T
cells can dramatically skew T cell cultures in favor of higher-
affinity T cell clones [22], we compared the binding properties
and the TCR genes expressed by T cells elicited by peptide
variants directly ex vivo. The T cells elicited by an effective
peptide-variant bound fluorescent MHC-tetramers containing
the native tumor antigen with a higher staining intensity.
These T cells did not cross-react with an ineffective peptide
variant, suggesting that the repertoires of T cells responding to
these variant vaccines were different and did not overlap. In
addition, the effective peptide variants elicited a repertoire of
T cells that was closely related in sequence to the T cells
elicited by the native TAA, expressing a common Jb sequence
and a common CDR3b motif, and the frequency of sequences
containing this CDR3b motif correlated with tumor protec-
tion. Thus, the effective peptide-variant vaccines enhanced
the expansion of T cells that respond to the native TAA, rather
than activating a new subset of T cells. Importantly, these
results demonstrate that T cells responding to native tumor
antigens can be effectively stimulated to prevent tumor
growth, provided they are activated through the TCR by the
appropriate signal. The implication of these results is that the
most effective peptide vaccines may be identified by
measuring the responses of tumor antigen-specific T cells
found in patients, rather than isolated T cell clones.
Materials and methods
Mice
Six- to eight-week-old female BALB/cAnNCr mice were
purchased from the National Cancer Institute/Charles River
Laboratories. All animal protocols were reviewed and
approved by the Institutional Animal Care and Use Com-
mittee of National Jewish Health.
Cells
Sf9 and High Five insect cells ([23], Invitrogen) were cultured
and infected as described [2, 17]. T cell clones were cultured
as described [9]. The T cell lines were cloned by limiting
dilution and expanded with 5 9 105/ml irradiated CT26
tumor cells expressing the costimulatory molecule B7 for
2 weeks prior to flow cytometry and TCR sequence analysis.
Peptides
bgal (TPHGAGRIL [24]), AH1 (SPSYVYHQF [16]), A5
(SPSYAYHQF [9]), 39 (MNKYAYHML [18]), 15
(MPKYAYHML [18]), WMF (SPTYAYWMF [2]), and F1A5
(FPSYAYHQF [17]) peptides were identified as described.
Soluble synthetic peptides were C95% pure (Chi Scientific).
Vaccination
Sf9 insect cells were infected with recombinant baculovi-
rus (BV) encoding Ld and beta-2-microglobulin molecules
covalently linked to peptides via a glycine-rich linker as
described [2, 25].
Antibodies and staining reagents
Preparation of the fluorescent Ld tetramer linked to the AH1
peptide using a disulfide trap or loaded with exogenous AH1
peptide has been described [17, 18]. Soluble TCRs con-
taining CDR3b motifs were prepared by inserting Vb8.3 and
Va6 gene segments expressed by the A5-4E11 or 39-1D4 T
cell clones into a BV expression vector [2]. Purified TCR
molecules were conjugated to fluorescent streptavidin
molecules as described and used to stain insect cells
expressing membrane-bound peptide-MHC molecules [2].
The median fluorescent intensity (MFI) of Ld high cells was
determined. Antibodies specific for the Ld molecule
(28.14.8S), CD8 (53–6.7, Southern Biotech), IFNc
(XMG1.2, eBioscience), B220 (RA3-6B2, BD Pharmigen),
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CD4 (RM4-5, BD Pharmigen), and MHC-II (M5/114.15.2,
BD Pharmigen) were used for flow cytometric analyses. The
B220, CD4, and MHC-II antibodies were analyzed in the
‘‘dump gate’’ for the tetramer, IFNc, and Vb staining
experiments. For costaining experiments, splenocytes from
vaccinated mice were stained with Ld-tet linked to the AH1
peptide with a disulfide trap and conjugated to steptavidin-
PE for 2 h at 37C to facilitate internalization and limit
competition between tetramers and Ld-tet linked to the F1A5
or WMF peptides conjugated to streptavidin-AF647 were
added and stained for an additional 2 h at 4C. All samples
were run on a BD FACSCaliber flow cytometer.
Intracellular cytokine staining
Splenocytes were stimulated with the indicated peptide for
5 h in the presence of monensin, a protein transport
inhibitor (GolgiStop, BD Cytofix/Cytoperm Plus Fixation/
Permeabilization Kit, BD Pharmingen), fixed, permeabil-
ized, and stained as described [17].
Tetramer decay and titration
For the decay assay, 2 9 106 splenocytes were stained in 96-
well plates with Ld-tet loaded with the AH1 peptide for 1 h at
RT. The AH1 tetramer with the disulfide trap was not used in
these experiments because its fluorescence intensity is not
reduced during the timeframe of this experiment. The cells
were washed extensively and resuspended in FACS buffer
(1x phosphate-buffered saline, 19 HEPES buffer, 0.1%
sodium azide, 2% fetal bovine serum) and 100 lg/ml F(ab)’
fragments of the Ld-specific antibody (28.14.8S). Approxi-
mately 2 9 105 cells were removed at each time point and
fixed in 1% paraformaldehyde. Total fluorescence (Tf) was
determined using the following formula [26]:
Tf ¼ % of AH1-tetþof CD8þ cellsð Þ½
 MFI of AH1-tetþ populationð Þpeptide vaccine
 % of AH1-tetþ of CD8þ cellsð Þ½
 MFI of AH1-tetþ populationð Þbgalvaccine
Normalized fluorescence (Nf) was calculated by dividing
the Tf at each time point by the Tf at time 0. The natural log (ln)
of the Nf was plotted versus time and the data for each mouse
were fit to a one-phase exponential decay curve [(y = y0*e
(-kt) where y = ln Nf, k = decay constant, and t = time)]
using Prism version 4.0, Graphpad software. The half-lives
were calculated for each mouse [(half-life = -ln(2)/k)] and
compared using an unpaired two-tailed t test.
For the tetramer titration assay, splenocytes were stained
as above for 2 h at 4C. The MFI was calculated using the
following formula [26]: MFI = (Tf)/(% of AH1-tet
? of
CD8? cells). The MFI was plotted versus the concentration
of tetramer and fit to a one-site binding curve [Y =
(Bmax*X)/(KD ? X)] using Prism version 4.0, Graphpad
software. The KD values for each mouse were compared
using an unpaired two-tailed t test.
TCR sequencing
Approximately 1 9 105 CD8? AH1-tet? splenocytes were
separated with a MoFlo High-Performance Cell Sorter.
RNA was extracted using the RNeasy Mini Kit (Qiagen), and
cDNA was synthesized using the QuantiTect Reverse Tran-
scription Kit (Qiagen) according to the manufacturer’s
instructions. For the plasmid sequencing method, the cDNA
was PCR-amplified using the primer sets described in Sup-
plemental Table 1 [27–29]. Amplified DNA was cloned into
the pCR2.1 vector using the TOPO TA Cloning Kit (Invit-
rogen), and sequences were determined using an internal Cb
primer (Supplemental Table 1) and capillary DNA
sequencing instruments (ABI 3730s). For the high-through-
put method, the cDNA was PCR-amplified for 15 cycles
using a forward primer specific for all Vb8 family members
containing an adaptor sequence (in bold) and an internal
multiplex identifier (MID) sequence (in italics, Supplemental
Table 1) and a reverse primer specific for Cb containing a
different adaptor sequence (in bold, Supplemental Table 1).
PCR fragments were separated by gel electrophoresis, puri-
fied using the Gel Extraction Kit (Qiagen), and further
amplified 30 cycles using primers specific for the adaptor
sequences. After gel extraction and quantification, the PCR
products were combined and subjected to high-throughput
sequencing as previously described [30]. Sequences from
both methods were analyzed using a computer software
program developed by our laboratory that uses a BLAST-type
algorithm to identify Vb and Jb gene sequence information
[28, 31]. This program translated and aligned the sequences,
identified the MID sequences and sorted the results according
to each vaccine, distinguished the germline-encoded and
randomized CDR3b region of each sequence, calculated the
length of each CDR3b region, and determined the number of
sequences containing the shared CDR3b motif. The
sequences of the TCRs expressed by the T cell clones
(Fig. 6a) were determined by directly sequencing PCR
products amplified from their cDNA using the Vb8.3 and Cb
primers or Va6 primers.
Results
Vaccination with the F1A5 peptide elicits T cells
with higher affinity for the AH1 peptide
Previously identified peptide variants effectively stimu-
lated a tumor antigen-specific T cell clone both in vitro and
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in vivo, but elicited variable antitumor responses from the
endogenous T cell repertoire [17]. Vaccination with the
F1A5 peptide variant protected 90% of mice from tumor
growth, while tumors grew in all of the mice vaccinated
with the WMF peptide [2, 17]. The increased tumor pro-
tection afforded by the F1A5 peptide was attributed to the
expansion of more tumor-specific T cells that exhibited
effector function after stimulation with the AH1 peptide,
although the mechanism for this differential expansion of
functional T cells was not determined [17].
When factors such as CD8 and TCR expression levels
are considered, the relative median fluorescence intensity
(MFI) of multimerized peptide-MHC (tetramer) staining
reflects the binding affinity of T cells [26, 32–35].
Although direct affinity measurements would be ideal, this
cannot be performed with current technology on multi-
clonal T cells ex vivo. We hypothesized that the WMF
peptide was less effective because the T cells responding to
this vaccine bound to the AH1–Ld complex with lower
affinity. Thus, we measured the MFI of tetramer staining of
splenocytes from mice vaccinated with a previously
described insect cell vaccine expressing either an effective
(F1A5) or ineffective (WMF) variant peptide [2, 17]. We
detected differences in the relative MFI of the AH1-tetra-
mer? T cells (Fig. 1ai). After normalizing for the differ-
ences in the number of AH1-specific T cells (Supplemental
Fig. 1a), the F1A5-elicited T cells required a lower con-
centration of tetramer for half of the maximum number of
tetramer? cells to bind the AH1-tetramer (Fig. 1aii). Using
both the binding affinities and the EC50 values from these
data curves, we determined that the F1A5-elicited T cells
have a higher affinity for the AH1 tumor antigen than the
WMF-elicited T cells, consistent with our hypothesis
(Fig. 1aiii). These differences may be underestimated due
to the limitations of analog instruments and the loss of
linearity at higher fluorescence intensities. Due to the
limited number of AH1-specific cells in AH1-vaccinated
mice relative to background tetramer staining in bgal-
vaccinated mice, we were not able to reliably determine the
KD or EC50 of tetramer binding for these cells (Supple-
mental Fig 1b).
Since tetramer-dissociation rates correlate with peptide-
MHC/TCR affinities in some systems [26], we measured
the half-life (t1/2) of tetramer binding to the responding T
Fig. 1 T cells elicited by peptide-variant vaccines have different
affinity for the tumor antigen. a (i) Splenocytes from mice vaccinated
with the indicated peptides were stained with antibodies specific for
dump, CD8, and LFA-1 molecules and a titration of Ld-tet loaded with
the AH1 peptide. The MFI of AH1-tet? CD8? LFA-1? cells was
graphed after subtracting the fluorescence of tetramer-binding cells in
mice vaccinated with the irrelevant bgal peptide and fit to a one-site
binding curve. Error bars represent the SEM (n = 6 mice). Curves were
compared using an F test (***p \ 0.0001). (ii) Cells from (ai) were
graphed as a percentage of the maximum number of AH1-tet-binding
cells at each concentration of tetramer and fit to a sigmoidal dose–
response curve. Curves were compared using an F test (***p \ 0.0001).
(iii) KD and EC50 values were determined for individual mice using one-
site binding curves or sigmoidal dose–response curves as in (ai) and (aii)
and compared using a Student’s t test (**p = 0.002, *p = 0.0097,
n = 6 mice). b Splenocytes from (i) F1A5- or (ii) WMF-vaccinated
mice were stained as in (a). The total fluorescence of the dump- CD8?
LFA-1? AH1-tet? cells was determined at the indicated time. The
natural log (ln) of the normalized fluorescence was graphed and fit to an
exponential decay curve. (iii) The half-life of AH1-tet staining (t1/2) was
determined for each mouse and compared using a Student’s t test
(n.s. = not significant)
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cell repertoire (Fig. 1b). The average t1/2 of T cells from
F1A5- and WMF-vaccinated mice was not statistically
different (Fig. 1biii). Although many factors contribute to
Kd values calculated using multivalent interactions [35],
these observed avidity differences may be due to faster on-
rates rather than longer half-lives [36]. In summary, the
F1A5-elicited T cells bound to the AH1 antigen with
increased affinity, which may explain the previously
described improved effector function exhibited by T cells
responding to this peptide vaccine [17].
Few tumor-specific T cells cross-react
with both the F1A5 and WMF peptides
Next, we determined the mechanism involved in the
decreased affinity of the WMF-elicited T cells (Fig. 1) and
their decreased effector responses to the AH1 peptide [17].
Diminished T cell responses may have been caused by
incomplete activation of these cells or by the expansion of a
different repertoire of T cells with lower affinity. To distin-
guish these possibilities, we determined whether the effec-
tive and ineffective peptide variants elicit overlapping
repertoires of T cells. Splenocytes from vaccinated mice
were co-stained with the AH1-tetramer and variant tetramers
(Fig. 2a). It is intriguing that so few of these T cells cross-
reacted with both peptide variants, since they were designed
to stimulate the same AH1-specific T cell clone. However,
even among the AH1-specific T cells expanded by the vac-
cines, few cells bound to both variant tetramers (Fig. 2a, b).
Furthermore, the differences in the MFI of AH1-tetramer
staining (described in Fig. 1) were also detected in this
experiment and are shown in the dot plots (Fig. 2a).
In some systems, functional measurements more accu-
rately assess the number of antigen-specific T cells [37]. To
ensure the tetramer-binding experiments did not underes-
timate the number of T cells that cross-react with both
Fig. 2 The repertoire of T cells elicited by the variant peptides F1A5
and WMF is distinct and few cells overlap. a Splenocytes from mice
vaccinated with the indicated peptide were stained and gated on
CD8? dump- cells. Staining with the Ld-tet linked to the AH1 peptide
(y-axis) and Ld-tet linked to the F1A5 or WMF peptides (x-axis) is
shown. The dot plots are representative of 3 independent experiments.
b Splenocytes from multiple mice were stained as in (a), and the
percentage of tet? cells was determined by histogram analysis (n = 6
mice). Error bars represent the SEM, and groups were compared by
an unpaired two-tailed t test (*p = 0.0002, **p \ 0.0001).
c Splenocytes from (a) were assessed for intracellular IFNc produc-
tion after stimulation with the indicated peptides by staining with
antibodies specific for dump, CD8, and IFNc molecules. The events
shown are representative dot plots of 2 independent experiments. d T
cells from multiple mice were assessed for intracellular cytokine
production as in (c) (n = 3 mice). Although not shown in (c), IFNc
production by splenocytes stimulated with the AH1 peptide was
assessed using the same gating. Error bars represent the SEM, and
groups were compared by an unpaired two-tailed t test (*p = 0.0017,
**p \ 0.0001)
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peptide variants, we analyzed intracellular IFNc production
by splenocytes from vaccinated mice stimulated with either
the F1A5 or the WMF peptides (Fig. 2c, d). Similar to the
tetramer staining results, few T cells cross-reacted with
both variant peptides. In addition, as previously reported
[17], few WMF-elicited T cells produced IFNc after
stimulation with the AH1 peptide (Fig. 2d). Together, these
data suggest that vaccination with the F1A5 and WMF
peptides elicited different portions of the endogenous AH1-
specific T cell repertoire.
F1A5 and WMF peptides elicit different repertoires
of T cells
To directly characterize the TCR gene usage of the
AH1-specific T cells elicited by the peptide variants, we
co-stained splenocytes from vaccinated mice with the AH1-
tetramer and a panel of antibodies to the mouse TCR Vb
genes (Supplementary Fig. 2a). In addition to the F1A5 and
WMF peptides, we also analyzed the response to the native
tumor antigen and to three other previously characterized
peptide variants, 15 (ineffective), and A5 and 39 (effective)
[9, 17, 18]. All of these peptide variants were also selected
using the Vb8.3? CT T cell clone and, not surprisingly, they
elicited AH1-specific T cells that predominantly expressed
the Vb8 family of TCRs (Supplementary Fig. 2b).
Since most of the T cells responding to these peptide
vaccines expressed Vb8 TCR genes, it was not clear whe-
ther the peptides elicited different repertoires of T cells.
Thus, we analyzed the CDR3b and Jb sequences expressed
by AH1-specific T cells in mice vaccinated with the F1A5
and WMF peptides. The identified TCR sequences with in-
frame gene rearrangements are listed (Fig. 3). Nearly all of
the T cells elicited by the F1A5 peptide expressed TCRs
with the Jb2.6 gene segment (97%), in contrast to the
WMF-elicited TCR sequences that encoded several differ-
ent Jb gene segments (72% Jb2.6). While there was some
junctional diversity in the F1A5-elicited TCR sequences,
we identified a shared three amino acid motif in the pre-
dicted CDR3b loop that was absent from the WMF-elicited
TCR sequences. This CDR3b motif consisted of a glycine
or alanine residue, followed by a large polar residue and the
tyrosine residue of Jb2.6 (Fig. 3). The first two amino acids
of the motif were not germline-encoded, but encoded by
different frames of Db2 in combination with N-nucleotides.
A second CDR3b pattern consisting of a glycine residue,
followed by a glycine or alanine residue may also be unique
to mice vaccinated with effective peptides. Strikingly, most
of the TCRs used a Jb2.6 segment that was truncated during
rearrangement at its N-terminus precisely at the tyrosine
residue. This tyrosine residue is unique to Jb2.6 and is
predicted to lie on the exposed portion of the CDR3b loop
Fig. 3 The AH1-specific T cells elicited by the F1A5 peptide express
TCRs with the Vb8.3 and Jb2.6 gene segments and a common
CDR3b motif, and are different from the T cells elicited by the WMF
peptide. 1AH1-tet? cells from the spleens of 5 mice vaccinated with
the indicated peptide were pooled, separated by FACSorting, and the
gene segments encoding Vb8.3 TCRs were sequenced. 2Replicates:
the number of analyzed sequences that encoded a particular amino
acid sequence. 3Codons: the number of nucleotide sequences that
encoded a particular amino acid sequence. 4The sequences were
aligned using the shared cysteine residue in the Vb sequence and the
shared phenylalanine residue in the Jb sequence. Germline-encoded
sequences are shown as normal text, and sequence encoded by ‘‘n’’
nucleotide additions is shown in italics. Capital letters indicate the
CDR3b loop. 6Sequences encoding the common CDR3b motif,
consisting of a small hydrophobic residue, followed by a larger polar
residue, followed by the tyrosine residue encoded by the Jb2.6 gene
segment, are shown in bold. 7The Jb gene segments encoded by each
sequence are listed
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available for contact with peptide-MHC [38]. A second
common feature of nearly all of the F1A5-elicited Vb8.3? T
cells was a relatively short CDR3b length of 10 amino
acids. Although the structural analysis of these interactions
has yet to be performed, it is tempting to suggest that the
short CDR3b loop and the tyrosine residue in the CDR3b
motif are required for more stable interactions with the
tyrosine residues at positions 4 or 6 of the AH1 peptide.
These results are consistent with the affinity analyses and
tetramer staining data and demonstrate that vaccination
with the effective F1A5 and ineffective WMF peptides
elicits different repertoires of AH1-specific T cells.
Effective and ineffective peptides elicit different
repertoires of AH1-specific T cells
To determine whether the frequency and number of AH1-
specific T cells expressing the CDR3b motif correlates with
tumor protection, we extended the repertoire analysis to the
responses elicited by the native tumor antigen and other
previously identified peptide variants using two different
techniques. We sorted AH1-specific T cells from individual
vaccinated mice, generated cDNA, and performed PCR
using Vb8 and Cb primers. Between 1,000 and 35,000,
sequences were obtained per mouse using the Roche 454
Sequencing System and around 20 sequences were obtained
per mouse using standard sequencing methods (Supple-
mental Table 1). We first verified that both techniques pro-
duce similar results by comparing the sequences obtained
from the same preparation of cDNA using either method
(Fig. 4). Both sequencing methods revealed that Vb8.3? T
cells responding to the native tumor antigen express the
CDR3b motif, similar to the T cells responding to an effec-
tive peptide variant, the A5 peptide. Many identical
sequences were identified from the same cDNA sample
(Fig. 4a) and the frequencies of sequences expressing the
Jb2.6 gene segment and the CDR3b motif for most of the
samples were similar (Fig. 4b, c), demonstrating that stan-
dard sequencing methods and high-throughput sequencing
give similar results.
Fig. 4 T cells elicited by the native tumor antigen are similar to those
elicited by an effective peptide variant, and similar results are obtain
with plasmid and high-throughput sequencing methods. a 1This figure
is formatted as in Fig. 3. 2Gray shaded regions indicate CDR3b
sequences that were identified using both traditional sequencing
methods of plasmids encoding the PCR-amplified region (left) or
high-throughput sequencing of PCR products amplified from the same
cDNA (right). b Vb8.3 TCR sequences were amplified from the
cDNA of AH1-specific cells isolated from vaccinated mice and
sequenced using traditional sequencing methods (white bars) or high-
throughput sequencing (patterned bars). The percentage of Vb8.3
TCR sequences encoding the Jb2.6 gene segment was calculated for
each sample. Error bars represent the 95% confidence intervals
(**p = 0.008). c As in (b), the average percentages of sequences
encoding the common CDR3b motif were calculated for each sample.
Error bars represent the 95% confidence intervals (*p = 0.017)
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Similar to the AH1-elicited TCR sequences, many of the
Vb8.3? TCRs elicited by the effective A5, F1A5, and 39
peptides expressed the Jb2.6 gene segment and the CDR3b
motif (Fig. 5a, b). The distribution of CDR3b lengths
expressed by T cells elicited by the effective peptides was
also more similar to the AH1-elicited T cells than those
elicited by the WMF peptide (Fig. 5c, d). Peptide 15
elicited a highly variable repertoire of T cells, consistent
with its variable tumor protection and other previously
measured T cell responses [17, 18]. These data suggest that
the T cells elicited by the effective peptides and the native
tumor antigen were related, expressing a heavily selected
CDR3b motif, which may be involved in the specific rec-
ognition of the AH1–Ld complex.
Combining the data for the effective and ineffective
peptides, we found a significant increase in the frequency
of sequences encoding the Jb2.6 gene segment and the
CDR3b motif in TCRs elicited by the effective peptides
(Fig. 5e). Furthermore, there was a statistically significant
correlation between the frequency of both the Jb2.6 gene
segment and the CDR3b motif and tumor-free survival
afforded by these peptide vaccines (Fig. 6f, g). Finally, we
estimated the number of Vb8.3? T cells expressing the
CDR3b motif in the spleens of vaccinated mice. Effective
peptide vaccines have significantly more of these cells
(Fig. 5h), suggesting that the increased frequency and
number of Vb8.3? T cells expressing the CDR3b motif in
mice vaccinated with effective peptide vaccines may con-
tribute to effective antitumor immunity. We found similar
trends among the Vb8.1? T cells (Supplemental Fig. 3),
but not the Vb8.2? T cells (data not shown).
Surprisingly, although these junctional sequences were
similar to that expressed by the CT T cell clone (Fig. 6a),
we did not find the exact CT-TCR sequence in these mice
or in the mice vaccinated with the peptide variants. The
absence of the CT T cell clone in this study suggests that
this clone is not representative of the endogenous repertoire
of T cells responding to these vaccines and explains the
lack of cross-reactivity between the F1A5- and WMF-
elicited repertoires (Fig. 2). Perhaps the different mode of
immunization (whole cell irradiated CT26-GM [9]) and the
in vitro expansion used to generate the CT clone accounts
for its dominance in those studies, and absence here.
TCRs containing the CDR3b motif bind to the WMF
peptide with lower affinity
To study the binding properties of the motif-containing T
cells described above, we required both the b- and a-chain
sequences of the TCRs identified in Figs. 3 and 4. We
expanded and cloned AH1-specific T cells from vaccinated
mice as described [9]. The TCR genes expressed by these T
cell clones did not reflect the sequencing results we
obtained from fresh uncultured splenocytes, particularly for
the T cell clones from mice vaccinated with the ineffective
peptide variants (Fig. 6a). However, we obtained several
antigen-specific T cell clones that expressed TCRs con-
taining the CDR3b motif and that had identical Vb chains
as some of those identified ex vivo. These T cell clones
expressed a Va6 TCR, distinct from the Va4.11 TCR
expressed by the CT T cell clone (Fig. 6a).
To determine the binding properties of TCRs containing
the CDR3b motif, we subcloned the TCR molecules
expressed by the A5-4E11 and the 39-1D4 T cell clones
(Fig. 6a) into a BV expression vector. The sequences of
these TCRs were highly selected in mice vaccinated with
AH1, A5, and F1A5 peptides and not identified in mice
vaccinated with the ineffective 15 and WMF peptides. We
previously showed that the relative binding of multimeric-
soluble TCRs to peptide–MHC complex expressed on
BV-infected insect cells correlates with the affinity of
monomeric TCR for the peptide–MHC complex determined
by surface plasmon resonance [17, 18, 33, 39, 40].
Therefore, we stained insect cells expressing each of the
peptide variant–Ld complexes with fluorescent multimeric
TCRs derived from the A5-4E11 and 39-1D4 clones. The
soluble TCRs bound to insect cells expressing the native
tumor antigen, but not the irrelevant bgal peptide, dem-
onstrating that these TCRs are specific for the AH1 peptide
(Fig. 6b, c). The staining intensity of insect cells express-
ing the WMF peptide was significantly lower, indicating
that this CDR3b motif-containing TCR does not bind
efficiently to the WMF peptide (Fig. 6b). The binding of
the 39-1D4 TCR more closely correlated with its repre-
sentation in the ex vivo repertoire analysis, binding to the
A5 and F1A5 peptides and not to the WMF peptide
(Fig. 6c). The low-affinity interaction between the CDR3b
motif-containing TCRs and the WMF peptide provides a
simple mechanistic explanation for the absence of these
cells following vaccination with the WMF peptide.
Discussion
Although the peptide variants used in our study effectively
stimulated a tumor-specific T cell clone in vitro, they
elicited variable responses from the endogenous T cell
population. In this study, we found that effective cancer
peptide vaccines stimulate T cells with hypervariable
regions similar to those that respond to the natural tumor
antigen, not a de novo T cell repertoire. These results
suggest that the heterogeneity in the repertoire of AH1-
specific T cells contributes to the ineffectiveness of some
of the peptide-variant vaccines.
Similar to our results, a study of the T cell response to
the Melan-A/MART-126–35 TAA showed that the TCRb
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Fig. 5 T cells elicited by effective peptide variants express Vb8.3 TCRs
with a CDR3b motif that correlates with tumor protection. a The average
percentages of sequences encoding the Jb2.6 gene segment were
calculated for the sequences of the Vb8.3-expressing TCRs from
vaccinated mice (analyzed as in Fig. 4). Symbols represent individual
mice analyzed by traditional sequencing methods (black) or high-
throughput sequencing (gray). The bar indicates the mean, and groups
were compared using a Student’s t test (*p \ 0.05, **p \ 0.009, n = 4
mice). b As in (a), the average percentages of sequences encoding the
common CDR3b motif were calculated for each vaccine. c The number
of amino acids encoded in the CDR3b loop of each Vb8.3 sequence was
determined. The percentage of sequences encoding the indicated
CDR3b length was calculated for each mouse, as in traditional
spectratyping analysis. The errors bars represent the SEM (n = 4
mice). d The average length of the CDR3b chains was determined as in
(c) for the Vb8.3 sequences and compared using a Student’s t test
(*p \ 0.05, ***p = 0.007, n = 4 mice). e The average percentage of
sequences encoding the Jb2.6 gene segment (left) or the CDR3b motif
(right) was calculated for the effective (A5, F1A5, and 39 in black),
ineffective (15 and WMF in gray), and native peptides (white). Error
bars represent the SEM. Groups were compared using a Student’s t test
(**p = 0.0073, *p = 0.039). f The frequency of sequences encoding
the Jb2.6 gene segment (x-axis, from a) was plotted versus the frequency
of tumor-free survival observed for each vaccine (35), and a positive
correlation was found using a Spearman’s nonparametric correlation test
(r = 0.6256, p = 0.0032). g As in (f), the correlation of the frequency of
sequences encoding the CDR3b motif (x-axis, from b) and tumor-free
survival was analyzed (r = 0.5582, p = 0.0105). h The estimated
number of AH1-tet? T cells expressing Vb8.3 TCRs with the CDR3b
motif was determined by multiplying the average frequency of CDR3b
motif-containing TCR sequences (from b) by the number of Vb8.3?
AH1-tet? cells in the spleens of a separate cohort of mice (frequencies
from these mice are shown in Supplementary Fig. 1a) and compared
using a Student’s t test (***p \ 0.004)
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gene usage of the T cells responding to the native peptide
was broader than that responding to the peptide variant
[21]. They also identified a CDR3b motif that was shared
among several patients, a so-called public TCR, although
these motif-containing T cells were not among the domi-
nant clones identified in each patient and did not have a
higher functional avidity [21]. They concluded that the
repertoires responding to the peptide variants and the
native tumor antigen were subtly different but over-
lapping, and that the observed functional differences were
due to subtle structural changes in the TCR. In contrast, the
T cells responding to the ineffective peptide variants in our
study express a unique repertoire of TCRs that do not
overlap with the repertoire responding to the native tumor
antigen and that do not contain a significant fraction of the
shared CDR3b motif. Therefore, in our study, only the
effective peptide variants elicited a repertoire of T cells
that over-lapped with those responding to the native tumor
antigen.
The most effective peptide variants (A5 and F1A5) have
minimal amino acid sequence changes relative to the AH1
peptide. It is, therefore, not surprising that these vaccines
raise similar T cell repertoires. These data suggest that
peptides with conservative amino acid changes may be
more effective in stimulating antitumor immunity by elic-
iting a repertoire of T cells that mimics the response to the
native tumor antigen. In agreement with this premise,
another study concluded that substitutions at MHC-binding
positions create immunogenic peptide variants with an
overall similar structure to the native peptide [4]. However,
the opposite has also been shown in these studies. Peptides
specifically designed to encode conservative amino acid
changes were ineffective vaccines and raised a repertoire of
T cells different from that of the native tumor antigen [10,
20, 41]. These discrepancies suggest that even subtle amino
acid substitutions may cause unpredictable changes in the
repertoire and binding kinetics of the responding endoge-
nous T cells.
The T cells responding to the F1A5 peptide express
higher-affinity T cell receptors that functionally recognize
the AH1 TAA better than the T cells responding to the
ineffective peptide, WMF. Furthermore, soluble TCRs
encoding the common CDR3b motif do not bind efficiently
to the WMF peptide, providing a mechanistic explanation
for the lack of these TCRs in the responding repertoire. We
predict from these data that the structure of the WMF
peptide prevents productive interactions with TCRs con-
taining the common CDR3b motif. Specifically, the tryp-
tophan residue at position 7 of the WMF peptide may affect
the position of the adjacent tyrosine residue at position 6,
precluding its predicted interaction with the tyrosine resi-
due encoded by the Jb2.6 gene segment of the motif-con-
taining TCRs. Important for peptide vaccine development,
these results imply that T cells responding to the ineffective
variants (like WMF) cannot be ‘‘rescued’’ or forced to
respond to the tumor antigen with better adjuvants; they are
not anergic or improperly activated, they simply express T
cell receptors that interact poorly with the native tumor
antigen.
A clinically relevant strategy in the design of effective
peptide vaccines is to optimize the T cells used in the
identification of peptide variants. We selected our peptide
Fig. 6 CDR3b motif-containing TCRs bind poorly to the WMF
peptide. a 1T cell clones were screened for CD8? AH1-tet? Vb8.3?
cells and expanded using irradiated CT26-B7 tumor cells. T cell
clones were named after the vaccine used to generate the clone and
the plate and well number they were located in. 2Sequences of the
CDR3b region were determined after PCR amplification using Vb-
and Cb-specific primers. 3Sequences of the CDR3a region were
determined after PCR amplification using Va- and Ca-specific
primers. 4The cDNA sequence of 39-1D4 and A5-4E11 was
subcloned into a protein expression vector for binding studies. 5The
CT T cell clone was derived from a BALB/c mouse vaccinated with
irradiated CT26 tumor cells expressing the cytokine GM-CSF (9).
b Sequence encoding the TCRs derived from T cell clones expressing
Vb8.3 TCRs with the CDR3b motif (39-1D4 and A5-4E11) was
inserted into a BV expression vector, and purified TCR protein was
multimerized and conjugated to a fluorescent molecule. A5-4E11
(b) or 39-1D4 (c) TCR multimers and the Ld antibody 28.14.8 were
used to stain insect cells infected with BV encoding the indicated
peptide variant–Ld complex. The soluble TCR MFI was determined
for insect cells expressing similar levels of Ld molecules (n = 3).
Groups were compared using a Student’s t test (*p \ 0.05,
**p \ 0.01)
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variants based on improved binding to and activation of the
CT clone, an AH1-specific T cell clone that was in vitro
expanded and is not similar to those analyzed ex vivo
(Fig. 6). The T cell clones that were found in the endog-
enous repertoire bound to the peptides that elicit better
tumor-specific responses (Fig. 6). Therefore, we predict
that peptide variants selected with an ex vivo tumor-spe-
cific repertoire, rather than an in vitro selected T cell clone,
may be the most effective peptides for cancer vaccines.
Due to the unpredictable nature of the responding T cell
repertoire, even if optimal T cells are used for peptide
selection, ineffective peptides may be unavoidable in
peptide-variant vaccine development. Therefore, a general
strategy to improve the response to peptide variants such as
the WMF peptide should be considered. In this particular
case, rather than providing additional adjuvants or cyto-
kines during T cell activation, the repertoire of the T cell
response needs to be re-focused to those with high affinity
for the native tumor antigen. Although strategies to engi-
neer T cells with receptors that have high affinity for tumor
antigens have been developed and employed in the clinical
treatment for cancer [42, 43], effective antitumor immunity
may be more easily achieved by ‘‘boosting’’ the peptide-
variant responses with native tumor antigens [14, 44]. This
strategy may increase the number of high-affinity T cells
that cross-react with native tumor antigens and reduce
competition with T cells that only bind to peptide variants.
In summary, peptide-variant vaccines improve the pro-
liferation and activation of T cells that respond to native
tumor antigens. Because the T cell response is unpredict-
able and different for every antigen, optimal peptide vari-
ants may be most successfully identified using a
representative TAA-specific T cell population to select
preferred residue changes from a large and random set of
peptides.
Acknowledgments This work was supported by NCI CA109560
and ACS RSG-08-184-01-LIB. K.R.J. and J.D.B. were supported in
part by the Cancer Research Institute Predoctoral Emphasis Pathway
in Tumor Immunology Fellowship.
Conflict of interest The authors have no conflicting financial
interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF,
Harris MN, Johnston D, Bystryn JC (2003) Vaccine-induced
CD8? T-cell responses to MAGE-3 correlate with clinical out-
come in patients with melanoma. Clin Cancer Res 9:657–662
2. Jordan KR, McMahan RH, Oh JZ, Pipeling MR, Pardoll DM,
Kedl RM, Kappler JW, Slansky JE (2008) Baculovirus-infected
insect cells expressing peptide-MHC complexes elicit protective
antitumor immunity. J Immunol 180:188–197
3. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer
immunoediting. Annu Rev Immunol 22:329–360
4. van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van
Hall T, Achour A (2009) Design of agonistic altered peptides for
the robust induction of CTL directed towards H-2Db in complex
with the melanoma-associated epitope gp100. Cancer Res
69:7784–7792
5. Kersh GJ, Miley MJ, Nelson CA, Grakoui A, Horvath S, Don-
ermeyer DL, Kappler J, Allen PM, Fremont DH (2001) Structural
and functional consequences of altering a peptide MHC anchor
residue. J Immunol 166:3345–3354
6. Sharma AK, Kuhns JJ, Yan S, Friedline RH, Long B, Tisch R,
Collins EJ (2001) Class I major histocompatibility complex
anchor substitutions alter the conformation of T cell receptor
contacts. J Biol Chem 276:21443–21449
7. McWilliams JA, Sullivan RT, Jordan KR, McMahan RH,
Kemmler CB, McDuffie M, Slansky JE (2008) Age-dependent
tolerance to an endogenous tumor-associated antigen. Vaccine
26:1863–1873
8. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk
WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH (2000)
Self-tolerance to the murine homologue of a tyrosinase-derived
melanoma antigen: implications for tumor immunotherapy. J Exp
Med 191:1221–1232
9. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck
JP, Margulies DH, Pardoll DM (2000) Enhanced antigen-specific
antitumor immunity with altered peptide ligands that stabilize the
MHC-peptide-TCR complex. Immunity 13:529–538
10. Wang R, Wang-Zhu Y, Gabaglia CR, Kimachi K, Grey HM (1999)
The stimulation of low-affinity, nontolerized clones by heteroclitic
antigen analogues causes the breaking of tolerance established to an
immunodominant T cell epitope. J Exp Med 190:983–994
11. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR,
Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM,
Zarour HM (2008) Immunization with analog peptide in combi-
nation with CpG and montanide expands tumor antigen-specific
CD8? T cells in melanoma patients. J Immunother 31:781–791
12. Hou Y, Kavanagh B, Fong L (2008) Distinct CD8? T cell rep-
ertoires primed with agonist and native peptides derived from a
tumor-associated antigen. J Immunol 180:1526–1534
13. Iero M, Squarcina P, Romero P, Guillaume P, Scarselli E, Cerino
R, Carrabba M, Toutirais O, Parmiani G, Rivoltini L (2007) Low
TCR avidity and lack of tumor cell recognition in CD8(?) T cells
primed with the CEA-analogue CAP1-6D peptide. Cancer
Immunol Immunother 56:1979–1991
14. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M,
Weber JS, Lee PP (2004) Diversity and recognition efficiency of
T cell responses to cancer. PLoS Med 1:e28
15. Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C,
Rufer N, Romero P (2008) Unmodified self antigen triggers
human CD8 T cells with stronger tumor reactivity than altered
antigen. Proc Natl Acad Sci USA 105:3849–3854
16. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD,
Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll
DM, Jaffee EM (1996) The immunodominant major histocom-
patibility complex class I-restricted antigen of a murine colon
tumor derives from an endogenous retroviral gene product. Proc
Natl Acad Sci U S A 93:9730–9735
17. Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky
JE (2010) Peptide vaccines prevent tumor growth by activating T
Cancer Immunol Immunother (2012) 61:1627–1638 1637
123
cells that respond to native tumor antigens. Proc Natl Acad Sci U
S A 107:4652–4657
18. McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson
DB, Slansky JE (2006) Relating TCR-peptide-MHC affinity to
immunogenicity for the design of tumor vaccines. J Clin Invest
116:2543–2551
19. Sloan-Lancaster J, Allen PM (1996) Altered peptide ligand-
induced partial T cell activation: molecular mechanisms and role
in T cell biology. Annu Rev Immunol 14:1–27
20. Le Gal FA, Ayyoub M, Dutoit V, Widmer V, Jager E, Cerottini
JC, Dietrich PY, Valmori D (2005) Distinct structural TCR rep-
ertoires in naturally occurring versus vaccine-induced CD8?
T-cell responses to the tumor-specific antigen NY-ESO-1. J
Immunother 28:252–257
21. Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P,
Speiser DE, Rufer N (2009) Fine structural variations of alpha-
betaTCRs selected by vaccination with natural versus altered self-
antigen in melanoma patients. J Immunol 183:5397–5406
22. Dietrich PY, Walker PR, Schnuriger V, Saas P, Perrin G, Guillard
M, Gaudin C, Caignard A (1997) TCR analysis reveals significant
repertoire selection during in vitro lymphocyte culture. Int
Immunol 9:1073–1083
23. Crawford F, Huseby E, White J, Marrack P, Kappler JW (2004)
Mimotopes for alloreactive and conventional T Cells in a peptide-
MHC display library. PLoS Biol 2:523–533
24. Gavin MA, Gilbert MJ, Riddell SR, Greenberg PD, Bevan MJ
(1993) Alkali hydrolysis of recombinant proteins allows for the
rapid identification of class I MHC-restricted CTL epitopes.
J Immunol 151:3971–3980
25. Jordan KR, Crawford F, Kappler JW, and Slansky JE (2009)
Vaccination of mice with baculovirus-infected insect cells
expressing antigenic proteins. Current protocols in immunology/
edited by John E Coligan et al. [Chapter 2:Unit 2 15]
26. Savage PA, Boniface JJ, Davis MM (1999) A kinetic basis for T
cell receptor repertoire selection during an immune response.
Immunity 10:485–492
27. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky
P (1993) The sizes of the CDR3 hypervariable regions of the murine
T-cell receptor beta chains vary as a function of the recombined
germ-line segments. Proc Natl Acad Sci USA 90:4319–4323
28. Arden B, Clark SP, Kabelitz D, Mak TW (1995) Mouse T-cell
receptor variable gene segment families. Immunogenetics
42:501–530
29. Lefranc MP, Giudicelli V, Ginestoux C, Bodmer J, Muller W,
Bontrop R, Lemaitre M, Malik A, Barbie V, Chaume D (1999)
IMGT, the international ImMunoGeneTics database. Nucl Acids
Res 27:209–212
30. Wang C, Sanders CM, Yang Q, Schroeder HW Jr, Wang E,
Babrzadeh F, Gharizadeh B, Myers RM, Hudson JR Jr, Davis
RW, Han J (2010) High throughput sequencing reveals a complex
pattern of dynamic interrelationships among human T cell sub-
sets. Proc Natl Acad Sci U S A 107:1518–1523
31. Barth RK, Kim BS, Lan NC, Hunkapiller T, Sobieck N, Winoto
A, Gershenfeld H, Okada C, Hansburg D, Weissman IL et al
(1985) The murine T-cell receptor uses a limited repertoire of
expressed V beta gene segments. Nature 316:517–523
32. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA,
Sewell AK (2009) Tricks with tetramers: how to get the most
from multimeric peptide-MHC. Immunology 126:147–164
33. Crawford F, Kozono H, White J, Marrack P, Kappler J (1998)
Detection of antigen-specific T cells with multivalent soluble
class II MHC covalent peptide complexes. Immunity 8:675–682
34. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999)
Isolation of high avidity melanoma-reactive CTL from hetero-
geneous populations using peptide-MHC tetramers. J Immunol
162:2227–2234
35. Fahmy TM, Bieler JG, Edidin M, Schneck JP (2001) Increased
TCR avidity after T cell activation: a mechanism for sensing low-
density antigen. Immunity 14:135–143
36. Govern CC, Paczosa MK, Chakraborty AK, Huseby ES (2010)
Fast on-rates allow short dwell time ligands to activate T cells.
Proc Natl Acad Sci U S A 107:8724–8729
37. McWilliams JA, McGurran SM, Dow SW, Slansky JE, Kedl RM
(2006) A modified tyrosinase-related protein 2 epitope generates
high-affinity tumor-specific T cells but does not mediate thera-
peutic efficacy in an intradermal tumor model. J Immunol
177:155–161
38. Gras S, Kjer-Nielsen L, Burrows SR, McCluskey J, Rossjohn J
(2008) T-cell receptor bias and immunity. Curr Opin Immunol
20:119–125
39. Huseby ES, Crawford F, White J, Marrack P, Kappler JW (2006)
Interface-disrupting amino acids establish specificity between T
cell receptors and complexes of major histocompatibility com-
plex and peptide. Nat Immunol 7:1191–1199
40. White J, Crawford F, Fremont D, Marrack P, Kappler J (1999)
Soluble class I MHC with beta2-microglobulin covalently linked
peptides: specific binding to a T cell hybridoma. J Immunol
162:2671–2676
41. Cole DK, Edwards ES, Wynn KK, Clement M, Miles JJ, Ladell
K, Ekeruche J, Gostick E, Adams KJ, Skowera A, Peakman M,
Wooldridge L, Price DA, Sewell AK (2010) Modification of
MHC anchor residues generates heteroclitic peptides that alter
TCR binding and T cell recognition. J Immunol 185:2600–2610
42. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC,
Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP,
Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis
SA, Rosenberg SA (2006) Cancer regression in patients after
transfer of genetically engineered lymphocytes. Science
314:126–129
43. Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S,
Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P,
Rosato A (2009) Reprogramming T lymphocytes for melanoma
adoptive immunotherapy by T-cell receptor gene transfer with
lentiviral vectors. Cancer Res 69:9385–9394
44. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konso-
lakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E,
Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V,
Mavroudis D (2007) Vaccination of patients with advanced non-
small-cell lung cancer with an optimized cryptic human telome-
rase reverse transcriptase peptide. J Clin Oncol 25:2727–2734
1638 Cancer Immunol Immunother (2012) 61:1627–1638
123
